Abdominal Visceral Infarction in 3 Patients with COVID-19 by Besutti, G. et al.
1926 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 8, August 2020
RESEARCH LETTERS
from an Asymptomatic Contact in Germany. N Engl J Med. 
2020;382:970–1. https://doi.org/10.1056/NEJMc2001468
  3. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval 
of novel coronavirus (COVID-19) infections. Int J Infect Dis. 
2020;93:284–6. https://doi.org/10.1016/j.ijid.2020.02.060
  4. Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al.  
Association of public health interventions with the  
epidemiology of the COVID-19 outbreak in Wuhan, China. 
JAMA. 2020 Apr 10 [Epub ahead of print]. https://doi.org/ 
10.1001/jama.2020.6130  
  5. National Health Commission. Questions and answers about 
the prevention and control of asymptomatic cases infected by 
2019-nCoV [in Chinese] 2020. [cited 2020 April 24].  
http://www.nhc.gov.cn/jkj/s3578/202003/718c79c96f3e464
09dd49303d41a00ef.shtml
  6. Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, et al.  
Potential presymptomatic transmission of SARS-CoV-2,  
Zhejiang Province, China, 2020. Emerg Infect Dis. 
2020;26:1052–4. https://doi.org/10.3201/eid2605.200198
  7. Wang FS, Zhang C. What to do next to control the 2019-nCoV 
epidemic? Lancet. 2020;395:391–3. https://doi.org/10.1016/
S0140-6736(20)30300-7
  8. Novel Coronavirus Pneumonia Emergency Response  
Epidemiology Team. Vital surveillances: the epidemiological 
characteristics of an outbreak of 2019 novel coronavirus  
diseases (COVID-19)—China, 2020. China CDC Weekly. 
2020;2: 113–122 [cited 2020 April 24]. http://weekly.chinacdc.
cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51
  9. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early 
transmission dynamics in Wuhan, China, of novel  
coronavirus-infected pneumonia. N Engl J Med. 
2020;382:1199–207. https://doi.org/10.1056/NEJMoa2001316
Addresses for correspondence: Zhoubin Zhang or Pengzhe Qin, 
Guangzhou Center for Disease Control and Prevention, No.1 Qide 
road, Guangzhou, 510440, China; email gzcdczzb@gzcdc.org.cn or 
petgyy@gmail.com
Abdominal Visceral Infarction 
in 3 Patients with COVID-19
Giulia Besutti, Riccardo Bonacini, Valentina Iotti, 
Giulia Marini, Nicoletta Riva, Giovanni Dolci, 
Mariarosa Maiorana, Lucia Spaggiari,  
Filippo Monelli, Guido Ligabue, Giovanni Guaraldi, 
Paolo Giorgi Rossi, Pierpaolo Pattacini,  
Marco Massari
Author affiliations: Azienda Unità Sanitaria Locale di Reggio 
Emilia–Istituto di Ricovero e Cura a Carattere Scientifico di Reggio 
Emilia (AUSL–IRCCS), Reggio Emilia, Italy (G. Besutti,  
R. Bonacini, V. Iotti, G. Marini, N. Riva, G. Dolci, M. Maiorana, 
L. Spaggiari, P.G. Rossi, P. Pattacini, M. Massari); University of 
Modena and Reggio Emilia Clinical and Experimental Medicine 
PhD Program, Modena, Italy (G. Besutti, M. Maiorana); University 
of Modena and Reggio Emilia, Modena (R. Bonacini, G. Dolci,  
F. Monelli, G. Ligabue, G. Guaraldi)
DOI: https://doi.org/10.3201/eid2608.201161
Frequent thrombotic events, mostly pulmonary embolisms, have been reported in patients with 
coronavirus disease  (COVID-19) (1–4). We describe 3 
cases of COVID-19 complicated by abdominal viscer-
al infarction that occurred in inhabitants of the Emilia 
Romagna region in northern Italy.
Patient 1, a 54-year-old male former smoker 
with a history of asthma and quiescent ulcerative 
colitis not receiving any treatment, was admitted 
to the emergency department (ED) on February 28, 
2020, for syncope. He was discharged after undergo-
ing chest radiography and brain computed tomog-
raphy (CT), the results of which were unremarkable. 
He returned to the ED after 5 days for treatment of 
dyspnea, fatigue, and fever. Blood tests revealed de-
creased oxygen saturation (94%), increased C-reac-
tive protein (CRP) level (5.38 mg/dL; reference <0.5 
mg/dL), and lymphopenia (0.69 × 103 cells/mm3; 
reference range 0.8–4 × 103 cells/mm3). Chest CT 
scan demonstrated bilateral viral pneumonia, and 
nasopharyngeal and oropharyngeal swab specimens 
were positive for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). He was hospitalized 
and treated with lopinavir/ritonavir (400/100 mg 
orally 2×/d), and hydroxychloroquine (200 mg oral-
ly 2×/d). He was discharged to home after 3 hospi-
tal days, on therapy; no anticoagulant prophylaxis 
was suggested. He was rehospitalized 6 days after 
discharge when he developed sharp right flank and 
lumbar pain, fever, and dysuria. Blood and urine 
tests revealed neutrophilia (9.9 × 103 cells/mm3; 
reference range 1.6–7.5 × 103 cells/mm3), increased 
lactate dehydrogenase (LDH) (1,507 U/L; reference 
range 28–378 U/L), increased CRP (1.43 mg/dL), 
and proteinuria (50 mg/dL). CT scan demonstrat-
ed a large right kidney arterial infarction (Figure, 
panel A). He was treated with low molecular weight 
A high incidence of thrombotic events has been report-
ed in patients with coronavirus disease (COVID-19), 
which is caused by severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2) infection. We report 3 
clinical cases of patients in Italy with COVID-19 who de-
veloped abdominal viscera infarction, demonstrated by 
computed tomography.
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heparin (LMWH) (6,000 UI 2×/d) and discharged to 
home after 4 days.
Patient 2, a 53-year-old man with hypertension 
and a history of mitral valve replacement (June 2019), 
came to the ED on March 11, 2020, with fever, cough, 
and sore throat. At admission, he had decreased oxy-
gen saturation (94%) and increased CRP (6.99 mg/
dL). Chest CT scan demonstrated bilateral viral pneu-
monia, and nasopharyngeal and oropharyngeal swab 
specimens were positive for SARS-CoV-2. He was 
hospitalized and treated with lopinavir/ritonavir 
(400/100 mg orally 2×/d) and hydroxychloroquine 
(200 mg orally 2×/d); he also received 2 administra-
tions of tocilizumab (8 mg/kg, an off-label use) on 
hospital day 3 because his respiratory function was 
worsening. Because of his previous mitral valve re-
placement, he was already being treated with anti-
platelet prophylaxis with acetylsalicylic acid but not 
with anticoagulants. On hospital day 6 he reported se-
vere left flank pain; blood tests revealed neutrophilia 
(11.74 × 103 cells/mm3) and increased LDH (932 U/L) 
and CRP (4.42 mg/dL). CT scan demonstrated large 
infarcted areas involving the spleen and the left kid-
ney (Figure, panels B,C). He was treated with LMWH 
(6,000 UI 2×/d) and discharged home after 7 days.
Patient 3, a 72-year-old man with stage 3 kidney 
failure, hypertension, previous myocardial infarc-
tion, and type 2 diabetes, came to the ED on March 
25, 2020, with shortness of breath and dry cough. At 
admission, he had increased CRP (19.3 mg/dL) and 
high glucose level (1,000 mg/dL; reference <100 mg/
dL) with severe metabolic acidosis. Nasopharyngeal 
and oropharyngeal swab specimens were positive for 
SARS-CoV-2. He was hospitalized, began antithrom-
botic prophylaxis with LMWH (4,000 UI 1×/d), and 
continued secondary prophylaxis with acetylsalicylic 
acid. He was transferred in the intensive care unit the 
day after admission; a few hours later, he developed 
severe abdominal pain. Blood tests revealed neu-
trophilia (17.69 × 103 cells/mm3) and increased LDH 
(1,510 U/L), CRP (48 mg/dL), and D-dimer (6,910 
ng/mL), with normal prothrombin time and acti-
vated partial thromboplastin time. Antiphospholipid 
antibodies were not detected. CT scan demonstrated 
small bowel ischemia associated with massive splenic 
infarction (Figure, panels D,E). He underwent resec-
tion of the ischemic bowel loop and splenectomy, was 
treated with heparin in continuous infusion, and was 
discharged from the ICU 2 days later. As of May 9, he 
was still hospitalized but his condition was improving.
Figure. Abdominal contrast-
enhanced computed tomography 
scans of 3 coronavirus disease 
patients with abdominal visceral 
infarction, Italy. A) Patient 1 
(axial view) showing intraarterial 
thrombi in the renal artery 
(arrow) and kidney and splenic 
infarctions (asterisk), seen as 
large wedge-shaped hypodense 
parenchymal areas. B, C) 
Patient 2 (B, coronal view; C, 
axial view) showing kidney and 
splenic infarctions (asterisks), 
seen as large wedge-shaped 
hypodense parenchymal areas. 
D, E) Patient 3 (D, coronal 
view; E, sagittal view), showing 
intraarterial thrombi in the 
superior mesenteric artery 
and its branches (arrows in D) 
and thoracic descending aorta 
(arrow in E), as well as small 
bowel ischemia (asterisks in 
D), seen as small bowel loops 
with decreased or absent wall 
enhancement. In patients 1 and 
2, scans did not show notable 
signs of atherosclerosis.
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Between the start of the SARS-CoV-2 outbreak 
in Reggio Emilia at the end of February and March 
24, the province has had 460 hospitalizations in all 
hospitals. Among these, 2 (0.4%) patients (1,2) had 
acute ischemic events involving abdominal viscera; 
therefore, these events should not be considered too 
rare. Visceral infarction is probably a clinical mani-
festation of the prothrombotic state that has been 
described in patients with COVID-19 (1–6). Consis-
tently, reports about pathological changes in organs 
other than the lungs describe parenchymal cells ne-
crosis and small-vessel thrombosis (7).
The possibility of abdominal visceral infarction 
during COVID-19 has major implications in clinical 
practice. First, when patients with COVID-19 report 
severe abdominal pain, visceral infarction should be 
considered in differential diagnosis and taken into 
account in laboratory and imaging diagnostic work-
ups. Second, this finding should further prompt the 
scientific community to stress the need to routinely 
use LMWH in patients with COVID-19 and to open 
the debate on the appropriate dosage. Finally, the 
prothrombotic state in patients with COVID-19 may 
justify therapeutic rather than prophylactic LMWH.
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After the 2003 severe acute respiratory syndrome coronavirus epidemic, the government and pub-
lic of Taiwan have been vigilant about the threat of 
emerging infectious diseases. The government of Tai-
wan took swift action to prevent coronavirus disease 
(COVID-19) importation and outbreaks (1). The public 
Taiwan has strictly followed infection control measures 
to prevent spread of coronavirus disease. Meanwhile, 
nationwide surveillance data revealed drastic decreases 
in influenza diagnoses in outpatient departments, posi-
tivity rates of clinical specimens, and confirmed severe 
cases during the first 12 weeks of 2020 compared with 
the same period of 2019.
